Plasma intact fibroblast growth factor 23 levels in women with anorexia nervosa by Otani, Makoto et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
BioPsychoSocial Medicine
Open Access Short report
Plasma intact fibroblast growth factor 23 levels in women with 
anorexia nervosa
Makoto Otani*, Yoshiyuki Takimoto, Junko Moriya, Kazuhiro Yoshiuchi and 
Akira Akabayashi
Address: Department of Stress Sciences and Psychosomatic Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
Email: Makoto Otani* - mootani-tky@umin.ac.jp; Yoshiyuki Takimoto - taki-tky@umin.ac.jp; Junko Moriya - jmoriya-tky@umin.ac.jp; 
Kazuhiro Yoshiuchi - kyoshiuc-tky@umin.ac.jp; Akira Akabayashi - akirasan-tky@umin.ac.jp
* Corresponding author    
Abstract
Background: Fibroblast growth factor (FGF)23 is a novel phosphaturic factor associated with
inorganic phosphate homeostasis. Previous human studies have shown that serum FGF23 levels
increase in response to a high phosphate diet. For anorexia nervosa (AN) patients, inorganic
phosphate homeostasis is important in the clinical course, such as in refeeding syndrome. The
purpose of this study was to determine plasma levels of intact FGF23 (iFGF23) in restricting-type
AN (AN-R) patients, binge-eating/purging-type AN (AN-BP) patients, and healthy controls.
Methods: The subjects consisted of 6 female AN-R patients, 6 female AN-BP patients, and 11
healthy female controls; both inpatients and outpatients were included. Plasma iFGF23, 1,25-
dihydroxyvitamin D (1,25-(OH)2D), and 25-hydroxyvitamin D (25-OHD) levels were measured.
Data are presented as the median and the range. A two-tailed Mann-Whitney U-test with
Bonferroni correction was used to assess differences among the three groups, and a value of p <
0.017 was considered statistically significant.
Results: There were no differences between AN-R patients and controls in the iFGF23 and 1,25-
(OH)2D levels. In AN-BP patients, the iFGF23 level (41.3 pg/ml; range, 6.1–155.5 pg/ml) was
significantly higher than in controls (3.8 pg/ml; range, not detected-21.3 pg/ml; p = 0.001), and the
1,25-(OH)2D was significantly lower in AN-BP patients (7.0 pg/ml; range, 4.2–33.7 pg/ml) than in
controls (39.7 pg/ml; range, 6.3–58.5 pg/ml; p = 0.015). No differences in plasma 25-OHD levels
were observed among the groups.
Conclusion: This preliminary study is the first to show that plasma iFGF23 levels are increased in
AN-BP patients, and that these elevated plasma FGF23 levels might be related to the decrease in
plasma 1,25-(OH)2D levels.
Findings
Fibroblast growth factor (FGF)23, a circulating 26 kDa
peptide produced by osteogenic cells, is a novel phospha-
turic factor. It is important for the regulation of inorganic
phosphate homeostasis and for vitamin D metabolism
[1]. FGF23 inhibits renal proximal tubule phosphate rea-
bsorption, increases renal phosphate excretion, and
reduces serum phosphate without affecting serum cal-
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cium. FGF23 also strongly suppresses 1,25-(OH)2D pro-
duction [2,3].
Anorexia nervosa (AN) is an eating disorder characterized
by decreased caloric intake, low weight, and reduced body
fat. To date, two subtypes have been identified: restricting-
type (AN-R); and binge-eating/purging-type (AN-BP). AN
is diagnosed by weight loss and refusal to maintain a min-
imal normal body weight, an intense fear of gaining
weight or becoming fat, a self-evaluation unduly influ-
enced by body shape and weight, and amenorrhea [4].
AN-R patients restrict food intake, while AN-BP patients
regularly engage in binge-eating and/or purging.
In patients with AN, refeeding syndrome is a well-known
phenomenon that occurs during the course of nutritional
rehabilitation; it is characterized by hypophosphatemia,
which may result in serious consequences, such as cardiac
dysrhythmia, delirium, and even sudden death [5].
Although inorganic phosphate homeostasis is important
in AN patients, no previous studies have examined
plasma FGF23 levels in AN. Therefore, the present study
determined plasma FGF23 concentrations in AN-R
patients, AN-BP patients, and healthy controls.
The subjects included 12 female AN patients who met the
diagnostic criteria of the Diagnostic and Statistical Manual
of Mental Disorders-Fourth Edition (DSM-IV) [4] and 11
healthy female controls. The 12 AN patients included 6
patients with AN-R and 6 patients with AN-BP. No
patients had a previous diagnosis of bulimia nervosa. The
study's cases included outpatients and inpatients of the
University of Tokyo Hospital. Except for proper doses of
antidepressants, anxiolytics, hypnotics, laxatives and
stomach agents, patients with AN-BP were treated with
lactomin (3 g/day; n = 1), lomerizine (10 mg/day; n = 1)
and pantethine (300 mg/day; n = 1), and AN-R patients
and controls did not receive drug therapy. Premorbid
renal dysfunction was an exclusionary criterion.
Blood samples were collected from all subjects after over-
night fasting. The protocol was approved by the Institu-
tional Ethics Committee of the University of Tokyo, and
written informed consent was obtained from all subjects
prior to enrollment in the study.
All blood samples were drawn into chilled tubes contain-
ing EDTA-2Na (1 mg/ml) and were then immediately cen-
trifuged at 4°C. Plasma portions were stored at -70°C
prior to analysis. Plasma concentrations of intact FGF23
(iFGF23) were measured using an ELISA kit (Immutopics,
San Clemente, CA, USA) (6,7), with a sensitivity of 1.0 pg/
ml, intra-assay variability of <4.4%, and inter-assay varia-
bility of <6.5%. All samples were analyzed in duplicate.
Plasma 1,25-(OH)2D and 25-OHD concentrations were
measured using RIA (SRL, Tokyo, Japan). Plasma calcium
and phosphate concentrations were measured using
standard laboratory methods (SRL).
A two-tailed Mann-Whitney U-test with Bonferroni cor-
rection was done after Kruskal-Wallis testing to assess dif-
ferences among the three groups. A usual two-tailed
Mann-Whitney U-test was used to assess differences
between AN-R patients and AN-BP patients when healthy
controls were missing data points. Values of p < 0.05 were
considered statistically significant on the Kruskal-Wallis
test and on the usual two-tailed Mann-Whitney U-test,
and values of p < 0.017 were considered statistically sig-
nificant on the two-tailed Mann-Whitney U-test with Bon-
ferroni correction. Spearman's rank-correlation
coefficients (ρ) was used to assess the relationship
between iFGF23 and age and body mass index (BMI) for
AN patients. All statistical calculations were performed
using SPSS for Windows version 10.0 (SPSS, Chicago, IL,
USA). All data are presented as the median and range.
Clinical profiles and biochemical data are summarized in
Table 1.
Plasma calcium levels in AN-R patients were significantly
increased when compared with controls (p < 0.001),
while there were no differences between AN-BP patients
and controls (p = 0.350). No statistically significant differ-
ences in plasma phosphate levels were observed among
the groups.
Plasma iFGF23 levels were significantly greater in AN-BP
patients than in controls (p = 0.001); there was no differ-
ence between AN-R patients and controls (p = 0.149; fig.
1). Plasma iFGF23 levels tended to be higher in AN-BP
than in AN-R patients, but this difference was not statisti-
cally significant (p = 0.041). For AN patients, iFGF23 val-
ues did not correlate significantly with age (ρ = 0.181, p =
0.574) or with BMI (ρ = -0.112, p = 0.728).
No differences in plasma 25-OHD levels were observed
among the groups. Plasma 1,25-(OH)2D was significantly
lower in AN-BP patients than in controls (p = 0.015) and
in AN-R patients (p = 0.015); there was no difference
between AN-R patients and controls (p = 0.733).
This is the first study to show that AN-BP patients have
elevated plasma iFGF23 levels. Plasma iFGF23 levels were
significantly greater in AN-BP patients than in healthy
controls, while there was no difference in plasma iFGF23
levels between AN-R patients and controls.
Previous reports showed that phosphate restriction signif-
icantly reduced FGF23 concentrations in healthy men and
women [8-10]. In patients with severe malnutrition and aBioPsychoSocial Medicine 2008, 2:10 http://www.bpsmedicine.com/content/2/1/10
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very limited phosphate intake, phosphate restriction is
considered to be responsible for decreased FGF23 levels.
In this study, the AN-R patients were all being treated as
inpatients or outpatients; therefore, they might have had
a certain amount of phosphate intake. This fact might
have contributed to the lack of a difference in iFGF23 lev-
els between AN-R patients and controls in the present
study.
Interestingly, plasma iFGF23 levels were significantly
higher in AN-BP than in healthy controls, while there
were no differences in plasma phosphate levels among the
groups. During binge eating, AN-BP patients eat a large
quantity of food at once, including foods such as choco-
lates, cakes, snacks, and sweet buns, which generally con-
tain moderate to large amounts of phosphate. In other
words, binge eating in AN-BP patients might be regarded
as acute phosphate loading. Previous reports found that,
in healthy men and women, FGF23 concentrations were
significantly increased by phosphate loading [9,10]; in
healthy men, serum iFGF23 increased significantly 8 h
after intake of 1,200 mg phosphate, compared to 8 h after
intake of 400 mg and 800 mg phosphate [11]. Thus, our
findings support the idea that AN-BP patients, most of
whom have regularly engaged in binge eating, have
increased plasma FGF23 levels due to the acute phosphate
loading that occurs with binge eating. No previous reports
have described the effects of binge eating on plasma
FGF23 levels.
An earlier report showed that frequent vomiting increased
serum amylase levels in AN patients [12]. The serum amy-
lase level is an established indicator of vomiting behavior
in AN patients. However, currently there is no established
indicator for binge eating behavior. This preliminary
study implies that plasma FGF23 levels might be a suita-
ble candidate as an indicator of binge eating in AN
patients.
The present study also found that AN-BP patients had a
significantly lower plasma 1,25-(OH)2D level than both
healthy controls and AN-R patients. Injection of recom-
binant FGF23 into normal and parathyroidectomized ani-
mals caused a reduction in serum 1,25-(OH)2D levels [2].
Elevated plasma FGF23 in AN-BP patients might decrease
plasma 1,25-(OH)2D levels.
Dot plots of plasma iFGF23 levels in AN patients and healthy  controls Figure 1
Dot plots of plasma iFGF23 levels in AN patients and 
healthy controls. The graphs depict median values (bars). 
Two-tailed Mann-Whitney U-tests with Bonferroni correc-
tion were used to assess differences among groups. A value 
of p < 0.017 was considered statistically significant. *p < 
0.017 vs. controls.
Table 1: Clinical profiles and biochemical data of women with anorexia nervosa and healthy controls
AN-R (n = 6) AN-BP (n = 6) Controls (n = 11) P
Body Mass Index (kg/m2) 16.0 * (13.8–17.4) 13.8 * (13.0–15.5) 19.7 (18.5–23.7) <0.001
Age (years) 19 (17–32) 31 (19–38) 27 (21–32) 0.034
age at the time of disease onset (years) 17 (16–30) 24 (14–34)
disease duration (yaers) 1.8 (0.5–3.0) 5.0 § (2.0–11.0)
frequency of binge eating None (none-none) 3.5/week (none-2–3/day)
frequency of vomiting None (none-none) 1/week § (none-2–3/day)
Ca (mg/dl) 10.2 * ‡ (9.5–10.7) 9.1 (7.9–9.4) 8.9 (8.4–9.6) 0.018
P (mg/dl) 3.4 (3.1–4.2) 3.5 (3.0–4.0) 2.9 (2.0–3.7) 0.029
1,25-(OH)2D (pg/ml) 34.4 (19.0–51.5) 7.0 * † (4.2–33.7) 39.7 (6.3–58.5) 0.023
25-OHD (ng/ml) 26 (19–30) 18 (11–31) 20 (12–28) NS
All values are described as median (minimum-maximum).
P values in the rightmost column were calculated using Kruskal-Wallis tests.
* p < 0.017 vs. controls, using a two-tailed Mann-Whitney U-test with Bonferroni correction.
† p < 0.017 vs. AN-R, using a two-tailed Mann-Whitney U-test with Bonferroni correction.
‡ p < 0.017 vs. AN-BP, using a two-tailed Mann-Whitney U-test with Bonferroni correction.
§ p < 0.05 vs. AN-R, using a usual two-tailed Mann-Whitney U-test.Publish with BioMed Central    and   every 
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Conflicting results have been reported regarding 1,25-
(OH)2D levels in AN patients. Some reports have shown
significantly lower serum or plasma 1,25-(OH)2D levels
in AN patients [13,14], while others have reported that
AN patients have normal 1,25-(OH)2D levels [15]. How-
ever, in these previous reports, the subjects were not cate-
gorized into AN-R and AN-BP groups. In the present
study, plasma 1,25-(OH)2D levels in AN-BP patients were
significantly lower than in AN-R patients. Our results indi-
cate the need for investigations that differentiate between
AN subtypes.
The present study has three limitations. First, the number
of AN patients was extremely small. Second, the volume
of binge eating and purging in the AN-BP patients before
participation in the study was not available. We were
therefore unable to completely assess whether binge eat-
ing primarily affects plasma FGF23 levels in AN patients.
Third, inorganic phosphate intake prior to participation
in the study was not assessed in AN-R patients. In future
studies, in addition to plasma FGF23, 1,25-(OH)2D and
25-OHD levels, inorganic phosphate intake, and the vol-
ume of binge eating prior to participation in the study
should be determined.
This preliminary study showed for the first time that
plasma iFGF23 levels are increased in AN-BP patients, and
that these elevated plasma FGF23 levels might decrease
plasma 1,25-(OH)2D levels. In AN-BP patients, plasma
FGF23 levels might be an indicator of binge-eating behav-
ior, which is characterized by acute phosphate intake.
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